6-benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | 35975-93-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 6-benzyl-4-oxo-1,4-dihydroquinolin-3-carboxylic acid；6-benzyl-4-oxo-1H-quinoline-3-carboxylic acid
• CAS: 35975-93-0；57278-49-6
• 化学式: C₁₇H₁₃NO₃
• 分子量: 279.295
• InChiKey: VKNMKLOFAQHPSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 6-benzyl-4-oxo-1,4-dihydroquinoline-3-carbonyl chloride
  参考文献：
  名称：

  2- [ 18 F]氟乙基叠氮化物在施陶丁格连接中的用途–结合GABA A受体的4-喹诺酮的制备和表征

  摘要：

  标记试剂2- [ 18 F]氟乙基叠氮化物用于无痕Staudinger连接。该反应用于获得结合了6-苄基-4-氧代-1，4-二氢喹啉-3-羧酸（2- [ 18 F]氟乙基）酰胺的GABA A受体。制备的放射性示踪剂的无衰减校正放射化学产率为7％，放射化学纯度> 95％，比放射性为0.9 GBq /μmol。该化合物在正常大鼠中脑渗透率低。还已经制备了一系列对GABA A受体具有纳摩尔至亚纳摩尔亲和力的氟代烷基4-喹诺酮类似物。

  DOI：

  10.1016/j.bmcl.2010.05.106
• 作为产物：
  描述：

  氨基二苯甲烷 在 sodium hydroxide 作用下， 以 二苯醚 、 乙醇 、 甲苯 为溶剂， 生成 6-benzyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
  参考文献：
  名称：

  源自喹诺酮类抗生素的新型 HIV-1 整合酶抑制剂。

  摘要：

  病毒酶整合酶对于 1 型人类免疫缺陷病毒 (HIV-1) 的复制至关重要，并且是抗逆转录病毒药物的剩余目标。在这里，我们描述了喹诺酮类抗生素的修饰，以生产新型整合酶抑制剂 JTK-303 (GS 9137)，该抑制剂阻止病毒酶的链转移。它具有喹诺酮类抗生素的核心结构，在链转移试验中的 IC50 为 7.2 nM，在急性 HIV-1 感染试验中的 EC50 为 0.9 nM。

  DOI：

  10.1021/jm0600139

文献信息

• [EN] AGENTS FOR USE IN THE TREATMENT OF CARDIOVASCULAR AND INFLAMMATORY DISEASES STRUCTURALLY BASED ON 4(1 H)-QUINOLONE<br/>[FR] AGENTS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES ET INFLAMMATOIRES AYANT UNE STRUCTURE BASÉE SUR LA 4(1H)-QUINOLONE
  申请人：UCL BUSINESS PLC

  公开号：WO2015189560A1

  公开（公告）日：2015-12-17

  The present invention provides a compound of formula I, a tautomer thereof, or a pharmaceutically acceptable salt or N-oxide thereof for use in the treatment or prevention of a cardiovascular disease or of an inflammatory disease or condition:

  本发明提供了一种式I的化合物，其互变异构体，或其药用可接受的盐或N-氧化物，用于治疗或预防心血管疾病或炎症性疾病或症状。
• [EN] PROCESSES FOR THE PREPARATION OF IVACAFTOR<br/>[FR] PROCÉDÉS DE PRÉPARATION D'IVACAFTOR
  申请人：LAURUS LABS PRIVATE LTD

  公开号：WO2017037672A1

  公开（公告）日：2017-03-09

  The present invention provides processes for the preparation of ivacaftor using novel intermediates and a process for its preparation.

  本发明提供了使用新型中间体制备依维卡夫醇的工艺以及其制备工艺。
• Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors
  作者：Motohide Sato、Hiroshi Kawakami、Takahisa Motomura、Hisateru Aramaki、Takashi Matsuda、Masaki Yamashita、Yoshiharu Ito、Yuji Matsuzaki、Kazunobu Yamataka、Satoru Ikeda、Hisashi Shinkai

  DOI：10.1021/jm900460z

  日期：2009.8.13

  Human immunodeficiency virus type 1 (HIV-1) integrase is a crucial target for antiretroviral drugs, and several keto-enol acid class (often referred to as diketo acid class) inhibitors have clinically exhibited marked antiretroviral activity. Here, we show the synthesis and the detailed structure-activity relationship of the quinolone carboxylic acids as a novel monoketo acid class of integrase inhibitors. 6-(3-Chloro-2-fluorobenzyl)- 1-((2,S)-1-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-4-oxo- 1,4-dihydroquinoline-3-carboxylic acid 51, which showed an IC50 of 5.8 nM in the strand transfer assay and an ED50 of 0.6 nM in the antiviral assay, and 6-(3-chloro-2-fluorobenzyl)-1-((2S)-1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-4-dihydroquinoline-3-carboxylic acid 49, which had an IC50 of 7.2 nM and an ED50 of 0.9 nM, were the most potent compounds in this class. The monoketo acid 49 was much more potent at inhibiting integrase-catalyzed strand transfer processes than 3'-processing reactions, as is the case with the keto-enol acids. Elvitegravir 49 was chosen as a candidate for further studies and is currently in phase 3 clinical trials.
• Investigating the Role of Metal Chelation in HIV-1 Integrase Strand Transfer Inhibitors
  作者：Alessia Bacchi、Mauro Carcelli、Carlotta Compari、Emilia Fisicaro、Nicolino Pala、Gabriele Rispoli、Dominga Rogolino、Tino W. Sanchez、Mario Sechi、Valentina Sinisi、Nouri Neamati

  DOI：10.1021/jm200851g

  日期：2011.12.22

  HIV-1 integrase (IN) has been validated as an attractive target for the treatment of HIV/AIDS. Several studies have confirmed that the metal binding function is a crucial feature in many of the reported IN inhibitors. To provide new insights on the metal chelating mechanism of IN inhibitors, we prepared a series of metal complexes of two ligands (HL1 and HL2), designed as representative models of the clinically used compounds raltegravir and elvitegravir. Potentiometric measurements were conducted for HL2 in the presence of Mg(II), Mn(II), Co(II), and Zn(II) in order to delineate a metal speciation model. We also determined the X-ray structures of both of the ligands and of three representative metal complexes. Our results support the hypothesis that several selective strand transfer inhibitors preferentially chelate one cation in solution and that the metal complexes can interact with the active site of the enzyme.
• [EN] RADIOLABELLED 1, 4 -DIHYDRO-4 -OXO-QUINOLINE 3-CARBOXYLIC ACID DERIVATIVES FOR PET AND SPECT IMAGING, AND IN-VITRO DETECTION OF THE GABA-A RECEPTOR<br/>[FR] AGENTS D'IMAGERIE
  申请人：GE HEALTHCARE LTD

  公开号：WO2009040377A3

  公开（公告）日：2010-07-22